We90
Pharmaceutical Company.

Conflicts of Interest: J. H. Chow serves on the Speaker’s Bureau for La Jolla
Azienda Socio-Sanitaria Territoriale-Cremona
Cremona, Italy
magiopi65@gmail.com

REFERENCES

DOI: 10.1213/ANE.000000000005401

In Response
We would like to thank Dr Giorgi-Pierfranceschi’s point about not reporting on deep venous thrombosis (DVT) prophylaxis, we believe this is very unlikely to have impacted our study’s results, as DVT prophylaxis is the standard of care for most hospitalized patients. Finally, we agree that establishing a lower thrombosis rate in patients taking aspirin would be an important step in confirming causality; however, aspirin’s benefit may not be solely related to its antiplatelet effects. Salicylic acid has important antiviral properties, which may contribute to its benefit in COVID-19.4 It is also important to recognize that during the pandemic, it was difficult to aggressively screen patients for DVT and pulmonary embolism (PE) because health care workers were trying to limit their exposure to infectious patients.

Jonathan H. Chow, MD
Department of Anesthesiology and Critical Care Medicine
George Washington University School of Medicine
Washington, DC
JChow@mfa.gwu.edu

Michael A. Mazzeffi, MD, MPH
Divisions of Critical Care Medicine and Cardiothoracic Anesthesiology
Department of Anesthesiology
University of Maryland School of Medicine
Baltimore, Maryland

REFERENCES

DOI: 10.1213/ANE.000000000005402

Keeping an Open Mind: Tracheostomy for Patients With Coronavirus Disease 2019

To the Editor
In their article for The Open Mind, Dr Bassi et al ask whether surgical tracheostomy is better than percutaneous tracheostomy in patients with coronavirus disease 2019. In regards to Dr Giorgi-Pierfranceschi’s point about not reporting on deep venous thrombosis (DVT) prophylaxis, we believe this is very unlikely to have impacted our study’s results, as DVT prophylaxis is the standard of care for most hospitalized patients. Finally, we agree that establishing a lower thrombosis rate in patients taking aspirin would be an important step in confirming causality; however, aspirin’s benefit may not be solely related to its antiplatelet effects. Salicylic acid has important antiviral properties, which may contribute to its benefit in COVID-19.4 It is also important to recognize that during the pandemic, it was difficult to aggressively screen patients for DVT and pulmonary embolism (PE) because health care workers were trying to limit their exposure to infectious patients.